The Small Molecule Discovery Shared Resource (SMD) collaborates with academics, government labs, and pharmaceutical companies to develop unique chemical probes and drug leads that address unmet medical needs in cancer.
Small molecule hits are identified using a variety of experimental screening technologies, including:
- biochemical screens measuring a specific activity
- cell assays using primary cells and cell lines
- small model organism screens using high-content imaging
- fragment screening by surface plasmon resonance and nuclear magnetic resonance (NMR)
- site-directed disulfide trapping (aka tethering).
A common approach for identifying compounds for further optimization. HTS uses robotic automation to allow testing of thousands to millions of compounds against one assay.
The SMD houses more than 200,000 molecules, including libraries based on diverse compounds, approved drugs, and bioactives with known mechanisms of action.
A complementary technology to high-throughput screening (HTS), fragment-based drug discovery has proven successful for many drug targets that are recalcitrant to traditional functional assays.
A site-directed fragment discovery method wherein bespoke libraries of disulfide-containing compounds are screened for binding to a native or engineered cysteine residue.
Our chemists are available to collaborate on programs on a personnel-support basis and can support grantwriting and fundraising efforts.